Organoid Sciences Enters 7.57B KRW Technology License Agreement with KRIBB - Strengthens IP for Regenerative Medicine and Drug Screening
Organoid Sciences signed an exclusive license agreement with KRIBB for organoid-based regenerative medicine and drug screening platform technology.
Total contract value is 7.57B KRW (upfront, milestone, and royalties), equivalent to 30.5% of equity (24.84B KRW), representing a significant financial commitment.
The contract is conditional; cost recognition and contract continuation depend on clinical and regulatory success, with milestone payments tied to future commercialization.
The agreement grants exclusive rights globally for cell therapy, disease modeling, and drug evaluation, enhancing long-term competitiveness.
[AI Summary]This technology licensing deal, despite the substantial cash outflow, strengthens the company's IP position and growth potential in regenerative medicine and drug screening, supporting long-term shareholder value.
KOSDAQ Filing Information
Filing: Major Management Decision Regarding Investment Judgment (Conclusion of Technology Introduction Agreement for Organoid-Based Regenerative Therapeutics and Drug Screening Platform)